EGFR and non-small cell lung carcinoma: A total of six RCTs [12–15, 19, 20] involving 1,244 patients with EGFR-mutant advanced NSCLC who received first-line A + T combination therapy or EGFR-TKI monotherapy were included in this meta-analysis.